{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:59:17Z","timestamp":1781143157495,"version":"3.54.1"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023B1515020082"],"award-info":[{"award-number":["2023B1515020082"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570424"],"award-info":[{"award-number":["82570424"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570587"],"award-info":[{"award-number":["82570587"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109413","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:09:35Z","timestamp":1776233375000},"page":"109413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cardiovascular adverse events in non-small cell lung cancer patients receiving osimertinib therapy: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"217","author":[{"given":"Wei-He","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jiu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Jie","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3505-4020","authenticated-orcid":false,"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109413_b0005","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109413_b0010","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jtho.2023.10.017","article-title":"MUC1-C is a common driver of acquired osimertinib resistance in NSCLC","volume":"19","author":"Haratake","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0015","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jaccao.2023.04.005","article-title":"How to treat EGFR-mutated non-smallcell lung cancer","volume":"5","author":"Belani","year":"2023","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jtho.2024.10.003","article-title":"The risk and reversibility of osimertinib-related cardiotoxicity in a real-world population","volume":"20","author":"Bak","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.48364","article-title":"Cardiac events and survival in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib","volume":"7","author":"Lin","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.lungcan.2026.109413_b0030","article-title":"An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109413_b0035","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an international cardio-oncology society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lungcan.2026.109413_b0040","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.20.01171","article-title":"Cardiac safety of osimertinib: a review of data","volume":"39","author":"Ewer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0045","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2026.109413_b0050","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1002\/cncr.35424","article-title":"Association between epidermal growth factor receptor-tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non-small cell lung cancer","volume":"130","author":"Byun","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0055","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer","author":"He","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0065","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jtho.2023.05.015","article-title":"Three-year safety, tolerability, and health-related quality of life outcomes of adjuvant osimertinib in patients with resected stage IB to IIIA EGFR-mutated NSCLC: updated analysis from the phase 3 ADAURA trial","volume":"18","author":"John","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0070","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241227677","article-title":"Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis","volume":"16","author":"Zhou","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.24.00533","article-title":"A multicenter open-label randomized phase ii study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-na\u00efve egfr-mutant metastatic non-small cell lung cancer (RAMOSE trial)","volume":"43","author":"Le","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0080","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108629","article-title":"Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis","volume":"205","author":"Gawli","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0090","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109413_b0095","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109413_b0100","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109413_b0105","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109413_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0115","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/jjco\/hyaa067","article-title":"Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan","volume":"50","author":"Ohe","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0120","doi-asserted-by":"crossref","first-page":"738-43.e2","DOI":"10.1016\/j.cllc.2024.06.012","article-title":"Osimertinib-related QTc prolongation: real-world incidence and impact of drug dosing on recurrence risk","volume":"25","author":"Chen","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0125","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1158\/1078-0432.CCR-20-4084","article-title":"Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)","volume":"27","author":"Bertino","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109413_b0130","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.24.00071","article-title":"Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study","volume":"42","author":"Blakely","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0135","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.clon.2021.01.011","article-title":"Can quantitative measures of T790M allelic fraction predict survival outcomes in patients receiving osimertinib? Observations from an early access programme","volume":"33","author":"Chan","year":"2021","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"10.1016\/j.lungcan.2026.109413_b0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/fon-2022-0919","article-title":"A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data","volume":"19","author":"Cheema","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0145","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/oncolo\/oyac193","article-title":"A phase II trial on osimertinib as a first-line treatment for EGFR mutation-positive advanced NSCLC in elderly patients: the SPIRAL-0 study","volume":"27","author":"Chihara","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2026.109413_b0150","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109413_b0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2020.03.009","article-title":"Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)","volume":"143","author":"Eide","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0160","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.21037\/tlcr-20-685","article-title":"Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma","volume":"9","author":"Gao","year":"2020","journal-title":"Transl Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109413_b0165","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0170","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + savolitinib to overcome acquired met-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.109413_b0175","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10637-024-01432-4","article-title":"Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer","volume":"42","author":"Hori","year":"2024","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.lungcan.2026.109413_b0180","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.2147\/CMAR.S339891","article-title":"A prospective observational study of osimertinib for chemo-naive elderly patients with EGFR mutation-positive non-small cell lung cancer","volume":"13","author":"Igawa","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.lungcan.2026.109413_b0185","article-title":"Trastuzumab-emtansine and osimertinib combination therapy to target HER2 bypass track resistance in EGFR mutation-positive NSCLC","volume":"4","author":"Jebbink","year":"2023","journal-title":"JTO Clin Res Rep."},{"key":"10.1016\/j.lungcan.2026.109413_b0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/prm2.12075","article-title":"Analysis of adverse drug reactions of Osimertinib in the 2nd-line treatment of EGFR mutant advanced nonsmall cell lung cancer","volume":"11","author":"Jiang","year":"2022","journal-title":"Precis. Med. Sci."},{"key":"10.1016\/j.lungcan.2026.109413_b0195","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtho.2022.12.021","article-title":"CD73 inhibitor oleclumab plus osimertinib in previously treated patients with advanced T790M-negative EGFR-mutated NSCLC: a brief report","volume":"18","author":"Kim","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0200","doi-asserted-by":"crossref","first-page":"985","DOI":"10.4143\/crt.2021.857","article-title":"Assessment of anti-tumor efficacy of osimertinib in non-small cell lung cancer patients by liquid biopsy using bronchoalveolar lavage fluid, plasma, or pleural effusion","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.lungcan.2026.109413_b0205","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/1759-7714.13378","article-title":"Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: a retrospective multicenter study of its real-world efficacy and safety in advanced\/recurrent non-small cell lung carcinoma","volume":"11","author":"Kishikawa","year":"2020","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.lungcan.2026.109413_b0210","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/cas.13511","article-title":"Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples","volume":"109","author":"Kiura","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2026.109413_b0215","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/onco.13951","article-title":"First-line osimertinib in patients with egfr-mutant advanced non-small cell lung cancer: outcome and safety in the real world: flower Study","volume":"27","author":"Lorenzi","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2026.109413_b0220","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109413_b0225","unstructured":"!!! INVALID CITATION !!! ."},{"key":"10.1016\/j.lungcan.2026.109413_b0230","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/1759-7714.13738","article-title":"Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial","volume":"12","author":"Lu","year":"2021","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.lungcan.2026.109413_b0235","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","article-title":"Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial","volume":"178","author":"Lv","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0240","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1222435","article-title":"CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients","volume":"14","author":"Majam","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109413_b0245","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.4103\/ijc.ijc_1374_21","article-title":"Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: results from a Phase IV study in India","volume":"59","author":"Malik","year":"2022","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0250","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.21873\/anticanres.15331","article-title":"Comparison between second- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with non-small-cell lung cancer: a retrospective analysis","volume":"41","author":"Mitsuya","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2026.109413_b0255","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109413_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061762","article-title":"Final results from a phase II trial of osimertinib for elderly patients with epidermal growth factor receptor t790m-positive non-small cell lung cancer that progressed during previous treatment","volume":"9","author":"Nakao","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lungcan.2026.109413_b0265","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2018.04.012","article-title":"Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer","volume":"121","author":"Nie","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0270","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM)","volume":"42","author":"Park","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0275","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","article-title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy","volume":"31","author":"Park","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0280","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00280-016-2992-z","article-title":"Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies","volume":"77","author":"Planchard","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109413_b0285","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12885-021-07922-5","article-title":"Osimertinib in advanced EGFR-T790Mmutation-positive non-small cell lung cancer patients treated within the special use medication program in Spain: OSIREX-spanish lung cancer group","volume":"21","author":"Provencio","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109413_b0295","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0300","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2023.02.023","article-title":"Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: the OPAL Study","volume":"185","author":"Saito","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0305","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.annonc.2021.11.010","article-title":"A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial","volume":"33","author":"Soo","year":"2022","journal-title":"Ann Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0315","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s00432-018-2754-x","article-title":"Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer","volume":"144","author":"Stratmann","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0320","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2021.02.019","article-title":"Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial","volume":"149","author":"Tanaka","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101183","article-title":"A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations","volume":"8","author":"Villaruz","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109413_b0330","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/1759-7714.14819","article-title":"Efficacy and safety of osimertinib plus anlotinib in advanced non-small-cell lung cancer patients after drug resistance","volume":"14","author":"Wang","year":"2023","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.lungcan.2026.109413_b0335","article-title":"The whole picture of first-line osimertinib for EGFR mutation-positive advanced NSCLC: real-world efficacy, safety, progression pattern, and posttreatment therapy (Reiwa Study)","volume":"5","author":"Watanabe","year":"2024","journal-title":"JTO Clin Res Rep."},{"key":"10.1016\/j.lungcan.2026.109413_b0340","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0345","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jtho.2019.02.001","article-title":"Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report","volume":"14","author":"Yang","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0350","article-title":"Efficacy and safety of combination treatment with apatinib and osimertinib after osimertinib resistance in epidermal growth factor receptor-mutant non-small cell lung carcinoma-a retrospective analysis of a multicenter clinical study","volume":"8","author":"Yang","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.lungcan.2026.109413_b0355","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1078-0432.CCR-20-1690","article-title":"Phase I study of the efficacy and safety of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant non-small cell lung cancer","volume":"27","author":"Yu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109413_b0360","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamaoncol.2020.1260","article-title":"Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1\/2 single-group open-label trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0365","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/1759-7714.14880","article-title":"Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations","volume":"14","author":"Zhang","year":"2023","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.lungcan.2026.109413_b0370","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-023-39139-4","article-title":"Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer","volume":"14","author":"Zhao","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2026.109413_b0375","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2022.06.012","article-title":"High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from the phase 2 multicenter POSITION20 trial","volume":"170","author":"Zwierenga","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0380","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","volume":"7","author":"Akamatsu","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0385","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40261-022-01145-7","article-title":"Combination of bevacizumab and osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.lungcan.2026.109413_b0390","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.7047","article-title":"Early increases in blood pressure and major adverse cardiovascular events in patients with renal cell carcinoma and thyroid cancer treated With VEGFR TKIs","volume":"21","author":"Narayan","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.lungcan.2026.109413_b0395","article-title":"Cardiovascular toxicity induced by vascular endothelial growth factor inhibitors","volume":"13","author":"Mihalcea","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.lungcan.2026.109413_b0400","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.lungcan.2020.10.021","article-title":"Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction","volume":"153","author":"Kunimasa","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109413_b0405","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109413_b0410","first-page":"38","article-title":"Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report","volume":"9","author":"Patel","year":"2023","journal-title":"Cardiooncology."},{"key":"10.1016\/j.lungcan.2026.109413_b0415","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:13:14Z","timestamp":1781140394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":83,"alternative-id":["S0169500226004745"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109413","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular adverse events in non-small cell lung cancer patients receiving osimertinib therapy: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109413"}}